Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) EBIT: 2012-2019

Historic EBIT for Larimar Therapeutics (LRMR) over the last 8 years, with Dec 2019 value amounting to -$45.7 million.

  • Larimar Therapeutics' EBIT rose 73.16% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.77%. This contributed to the annual value of -$45.7 million for FY2019, which is 25.31% up from last year.
  • As of FY2019, Larimar Therapeutics' EBIT stood at -$45.7 million, which was up 25.31% from -$61.1 million recorded in FY2018.
  • In the past 5 years, Larimar Therapeutics' EBIT ranged from a high of -$45.7 million in FY2019 and a low of -$73.8 million during FY2015.
  • For the 3-year period, Larimar Therapeutics' EBIT averaged around -$53.3 million, with its median value being -$53.0 million (2017).
  • In the last 5 years, Larimar Therapeutics' EBIT plummeted by 107.74% in 2015 and then increased by 25.31% in 2019.
  • Larimar Therapeutics' EBIT (Yearly) stood at -$73.8 million in 2015, then grew by 21.12% to -$58.2 million in 2016, then climbed by 8.98% to -$53.0 million in 2017, then declined by 15.33% to -$61.1 million in 2018, then climbed by 25.31% to -$45.7 million in 2019.